Mamyrova G, et al. - Authors evaluated the features of clinically amyopathic JDM (CAJDM), in which patients have characteristic rashes with little to no evidence of muscle involvement, to ascertain whether or not this is a distinct phenotype from JDM. As per data, CAJDM often have p155/140 (transcriptional intermediary factor 1) autoantibodies, have fewer systemic manifestations and receive less therapy and this may distinguish CAJDM from JDM. On multivariable modelling, a lower skeletal score and less frequent myalgias were revealed as the most important factors in distinguishing CAJDM from JDM.